Zimmer Biomet (ZBH) Q3 2025: U.S. Growth Accelerates to 5.6% as Innovation Cycle Gains Traction
Zimmer Biomet’s U.S. business delivered its strongest growth in over two years, fueled by new product adoption and robotics, but international headwinds and non-core segment volatility forced a more measured outlook. Leadership’s sharpened guidance philosophy and ongoing operational changes set a new tone for 2026, with innovation and execution under scrutiny for sustainable upside.
Summary
- U.S. Commercial Momentum Outpaces Expectations: Robust adoption of new knee and hip products and robotics drove sequential acceleration in the core U.S. market.
- International and Non-Core Volatility Triggers Guidance Reset: Late-quarter distributor and restorative therapy shortfalls led to a more conservative growth outlook.
- Innovation and Execution Remain Central to 2026 Trajectory: Management’s focus turns to sustaining product cycle gains and addressing commercial fragility.
Performance Analysis
Zimmer Biomet’s third quarter revealed a company in operational transition, with organic constant currency sales up 5% and standout U.S. growth of 5.6%—the highest since mid-2023. This acceleration was driven by strong adoption of recently launched products such as Persona Osseotide (cementless knee) and Oxford (partial knee), both exceeding internal post-training expectations. Robotics and navigation also contributed, with U.S. ROSA robotic-assisted procedures now exceeding half of knee implants, and technology/data sales up 20.3%.
However, late-quarter disruptions in Eastern Europe, Latin America, and restorative therapies (primarily hyaluronic acid injections) shaved roughly 120 basis points from growth, underscoring the fragility of non-core and emerging market segments. International growth slowed to 4.2%, with China and distributor order cancellations weighing on results. The SET (Sports, Extremities, and Trauma) segment delivered 3.6% growth, offset by a low-teens decline in restorative therapies. Gross margin improved to 72.6% on favorable mix, but operating margin expansion was modest due to increased commercial investment and integration of Paragon 28.
- U.S. Product Cycle Drives Share Recapture: Persona Osseotide now comprises nearly 30% of U.S. total knee implants, with penetration expected to exceed 50% by 2027.
- Robotics and Technology Placement Surges: ROSA placements and utilization hit a multi-year high, with U.S. accounts performing 400 basis points more knee implants robotically YoY.
- International and Non-Core Weakness Materializes: Distributor order cancellations and restorative therapies miss reduced quarterly growth by over 100 basis points.
Cash flow remained robust with $278 million in free cash flow for the quarter and inventory days on hand reduced by 10 days year over year, supporting ongoing capital flexibility.
Executive Commentary
"We grew sales 5% on an organic constant currency basis with our critical US business accelerating 330 basis points sequentially to 5.6% from 2.3% in the second quarter. This is the best revenue growth performance in the US since the middle of 2023... Importantly, we have identified the issues, are moving swiftly to address them, and are contemplating these headwinds in these three areas in the guidance that we are providing for the year 2025."
Yvonne Tornos, Chairman, President, and CEO
"We reported GAAP diluted earnings per share of $1.16 compared to GAAP diluted earnings per share of $1.23 in the prior year. Higher revenue, a decrease in acquisition and integration related charges, and lower share count were offset by higher interest expenses due to the Paragon 28 transaction, and a step-up in year-over-year tax tied to certain one-time favorable items in the prior year."
Sukhia Patia, CFO & EVP, Finance, Operations, and Supply Chain
Strategic Positioning
1. U.S. Channel and Product Innovation
Zimmer Biomet’s U.S. business is benefiting from a focused channel transformation, new sales leadership for ambulatory surgical centers (ASCs), and a sharpened sales incentive structure that ties compensation to revenue growth, margin, and free cash flow. The Magnificent Seven product cycle is driving market share recapture, particularly in knees and hips, while robotics (ROSA and Monogram) is deepening customer engagement and procedural penetration.
2. Addressing International and Non-Core Fragility
Late-quarter volatility in emerging markets and restorative therapies exposed execution gaps, prompting leadership and governance changes in affected regions. Management is embedding greater conservatism into guidance by excluding non-core revenue rebounds, signaling a shift to more reliable forecasting and performance accountability.
3. Capital Allocation and M&A Discipline
With over $1.3 billion in cash and a net leverage ratio in the low threes, Zimmer Biomet maintains flexibility to pursue targeted acquisitions (e.g., Paragon 28, Monogram) in high-growth segments while retaining optionality for share buybacks. The integration of Paragon 28 is on track, with organic growth in the upper single digits and a roadmap for sustained double-digit expansion.
4. Innovation Pipeline and Regulatory Milestones
Breakthroughs in product innovation remain a core growth lever: The recent PMDA approval of iodine-treated hips in Japan and FDA breakthrough device designation in the U.S. position Zimmer Biomet for premium pricing and clinical differentiation, with launches expected to drive meaningful revenue contribution in 2026 and beyond. The pipeline includes over 20 new products targeting efficiency, safety, and clinical outcomes.
5. Commercial Execution and Incentive Realignment
Incentive structures have been overhauled at all levels, with senior managers and sales reps now compensated on growth, margin, and pricing discipline. This realignment is intended to drive accountability and sustainable performance across business units.
Key Considerations
Zimmer Biomet’s quarter was defined by strong U.S. execution, a maturing innovation cycle, and the emergence of new commercial and operational guardrails. The company’s ability to sustain growth hinges on translating product adoption into durable market share gains while managing volatility in international and non-core segments.
Key Considerations:
- Innovation Cycle Momentum: Wave one of the Magnificent Seven product cycle is driving sequential U.S. acceleration; wave two (customer-centric innovation) and regulatory wins set up future upside.
- Guidance Philosophy Reset: Management is shifting to a more measured external stance, excluding non-core volatility from forecasts and focusing on high-probability revenue streams.
- Execution Fragility in International/Restorative Segments: Distributor order cancellations and reimbursement headwinds in hyaluronic acid injections highlight ongoing risk.
- Margin and Cash Flow Management: Ongoing inventory optimization and gross margin improvement support capital allocation flexibility and resilience to tariff and integration costs.
- Leadership and Incentive Realignment: Organizational changes and new incentive structures are designed to reinforce growth and accountability at every level.
Risks
Execution risk remains elevated in international and non-core segments, with distributor volatility and reimbursement changes posing ongoing headwinds. Market share in U.S. knees, while stabilizing, continues to lag peers, and the sustainability of innovation-driven gains will depend on successful commercial and operational follow-through. Tariff exposure, integration challenges, and macro uncertainty in emerging markets could impact both top-line and margin performance.
Forward Outlook
For Q4 2025, Zimmer Biomet guided to:
- Organic constant currency revenue growth of 3.5% to 4% (down from 3.5% to 4.5%)
- Adjusted EPS of $8.10 to $8.30 for the full year
For full-year 2025, management maintained:
- Reported revenue growth of 6.7% to 7.7% (including Paragon 28 and FX benefit)
- Free cash flow guidance of $1 billion to $1.2 billion
Management emphasized measured guidance philosophy, ongoing commercial and leadership changes, and a focus on innovation cycle execution as the company enters 2026.
- Restorative therapy and international volatility excluded from guidance
- U.S. momentum and new product launches seen as key growth catalysts
Takeaways
Zimmer Biomet’s Q3 marks a strategic inflection in commercial execution and guidance discipline.
- U.S. Outperformance Anchors Growth Narrative: Robust product cycle adoption and robotics utilization are driving sequential acceleration in the core U.S. business.
- Guidance and Execution Philosophy Shift: Management’s measured outlook and incentive realignment reflect a more conservative, risk-aware approach to forecasting and delivery.
- 2026 Watchpoints: Sustained U.S. momentum, innovation pipeline realization, and stabilization in international/non-core segments will determine the durability of Zimmer Biomet’s growth trajectory.
Conclusion
Zimmer Biomet delivered its strongest U.S. growth in years, underpinned by new product cycles and robotics, but late-quarter volatility and non-core weakness led to a more conservative guidance reset. Leadership’s sharpened focus on innovation, execution, and measured forecasting sets the stage for a pivotal 2026, with commercial discipline and operational resilience in the spotlight.
Industry Read-Through
Zimmer Biomet’s results highlight a broader medtech trend: product cycle innovation and robotics adoption are critical levers for share recapture and margin expansion in mature U.S. markets, while international volatility and non-core segment execution remain persistent risks across the sector. Premium pricing and regulatory wins for differentiated implants (e.g., iodine-treated devices) signal a path for margin uplift, but require robust commercialization and payer engagement. Capital allocation discipline and incentive realignment are increasingly central as medtech players navigate integration, tariff, and macro headwinds. Peers with similar product cycles or exposure to emerging markets should scrutinize their own execution and guidance philosophies as industry volatility persists.